José Alegre

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from Jose Alegre-Martin)
José Alegre-Martin.png

José Alegre, also known as José Alegre-Martin, MD, PhD, works in the Internal Medicine Division, CFS/ME Clinical Unit, Vall d ́Hebron University Hospital, Research Institute Vall d’Hebron Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.[1]

Education[edit | edit source]

  • 1982 - B.S. in Medicine, School of Medicine, Autonoma University of Barcelona, Spain[1]
  • 1990 - PhD, in Medicine, School of Medicine, Autonoma University of Barcelona, Spain[1]

EUROMENE[edit | edit source]

Dr. Alegre is a Member of the Clinical Research Enablers And Diagnostic Criteria Working Group for EUROMENE, a European Union not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[2]

Patents[edit | edit source]

  • June 2010, Patent No 10380071.0 – 2107: Use of alpha-1-antitrypsin for the preparation of medicaments for the treatment of chronic fatigue syndrome. Inventors: Dr. Ana Maria Garcia Quintana and Dr. José Alegre Martin, Propietor Grifols, SA.[1]
  • Dec 2010, Patent No US 2010/0331261: Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome. Inventors: Ana Garcia Quintana, José Alegre Martin.[1]

Notable studies[edit | edit source]


Talks and interviews[edit | edit source]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "CURRICULUM VITAE - Jose Alegre, MD; PhD" (PDF). euromene.eu. Retrieved February 5, 2020.
  2. ↑ Euromene: Clinical Research Enablers and Diagnostic Criteria Working Group
  3. ↑ Suárez, Andrea; Guillamó, Elisabet; Roig, Teresa; Blázquez, Alicia; Alegre, José; Bermúdez, Jordi; Ventura, José Luis; García-Quintana, Ana María; Comella, Agustí (June 2010). "Nitric Oxide Metabolite Production During Exercise in Chronic Fatigue Syndrome: A Case-Control Study". Journal of Women's Health. 19 (6): 1073–1077. doi:10.1089/jwh.2008.1255. ISSN 1540-9996.
  4. ↑ Curriu, Marta; Carrillo, Jorge; Massanella, Marta; Rigau, Josepa; Alegre, José; Puig, Jordi; Garcia-Quintana, Ana M; Castro-Marrero, Jesús; Negredo, Eugènia; Clotet, Bonaventura; Cabrera, Cecilia; Blanco, Julià (2013), "Screening NK-, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome", Journal of Translational Medicine, 11 (68), doi:10.1186/1479-5876-11-68
  5. ↑ Castro-Marrero, J.; Cordero, M.D.; Sáez-Francas, N.; Jimenez-Gutierrez, C.; Aguilar-Montilla, F.J.; Aliste, L.; Alegre-Martin, J. (2013), "Could mitochondrial dysfunction be a differentiating marker between chronic fatigue syndrome and fibromyalgia?", Antioxidants & Redox Signaling, 19 (15): 1855-1860, doi:10.1089/ars.2013.5346, PMID 23600892
  6. ↑ Faro, M.; Sáez-Francàs, N.; Castro-Marrero, J.; Aliste, L.; Collado, A.; Alegre, J. (2014), "Impact of the fibromyalgia in the chronic fatigue syndrome", Medicina Clinica (Barc), 142 (12): 519-525, doi:10.1016/j.medcli.2013.06.030, PMID 24387955
  7. ↑ Santamarina-Perez, Pilar; Eiroa-Orosa, Francisco Jose; Rodriguez-Urrutia, Amanda; Qureshi, Adil; Alegre, Jose (August 13, 2013). "Neuropsychological Impairment in Female Patients with Chronic Fatigue Syndrome: A Preliminary Study". Applied Neuropsychology: Adult. 21 (2): 120–127. doi:10.1080/09084282.2013.771264. ISSN 2327-9095.
  8. ↑ Castro-Marrero, J.; Cordero, M.D.; Segundo, M.J.; Sáez-Francàs, N.; Calvo, N.; Román-Malo, L.; Aliste, L.; Fernández de Sevilla, T.; Alegre, J. (2015), "Does Oral Coenzyme Q10 Plus NADH Supplementation Improve Fatigue and Biochemical Parameters in Chronic Fatigue Syndrome?", Antioxidants & Redox Signaling, 22 (8): 679–685, doi:10.1089/ars.2014.6181, PMID 25386668
  9. ↑ Sáez-Francàs, Naia; Calvo, Natalia; Alegre, José; Castro-Marrero, Jesús; Casas, Miguel (2015), "Childhood trauma in Chronic Fatigue Syndrome: focus on personality disorders and psychopathology", Comprehensive Psychiatry, 62: 13-19, doi:10.1016/j.comppsych.2015.06.010
  10. ↑ Faro, Mónica; Sáez-Francàs, Naia; Castro-Marrero, Jesús; Aliste, Luisa; Fernández de Sevilla, Tomás; Alegre, Jose (2015), "Gender Differences in Chronic Fatigue Syndrome", Reumatologia clinica, 12 (2), doi:10.1016/j.reuma.2015.05.007
  11. ↑ Calvo, Natalia; Sáez-Francàs, Naia; Valero, Sergi; Castro-Marrero, Jesús; Alegre Martín, José; Casas, Miquel (July 2017). "Diagnostic Concordance Between Categorical and Dimensional Instruments to Assess Personality Disorder in Chronic Fatigue Syndrome: PDQ-4+ and TCI-R". European Journal of Psychological Assessment. 33 (3): 158–165. doi:10.1027/1015-5759/a000281. ISSN 1015-5759.
  12. ↑ Castro-Marrero, Jesus; Sáez-Francàs, Naia; Santillo, Dafna; Alegre, Jose (March 2017). "Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome: Therapy and management in CFS/ME". British Journal of Pharmacology. 174 (5): 345–369. doi:10.1111/bph.13702. PMC 5301046. PMID 28052319.
  13. ↑ Castro-Marrero, J.; Faro, M.; Aliste, L.; Sáez-Francàs, N.; Calvo, N.; Martínez-Martínez, A.; de Sevilla, T.F.; Alegre, J. (2017), "Comorbidity in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Nationwide Population-Based Cohort Study", Psychosomatics, 58 (5): 533 - 543, doi:10.1016/j.psym.2017.04.010
  14. ↑ Cambras, T.; Castro-Marrero, J.; Zaragoza, MC.; Díez-Noguera, A.; Alegre, J. (2018), "Circadian rhythm abnormalities and autonomic dysfunction in patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", PLoS ONE, 13 (6): e0198106, doi:10.1371/journal.pone.0198106
  15. ↑ Castro-Marrero, Jesús; Zaragozá, Maria Cleofé; González-Garcia, Sergio; Aliste, Luisa; Sáez-Francàs, Naia; Romero, Odile; Ferré, Alex; Fernández de Sevilla, Tomás; Alegre, José (2018), "Poor self-reported sleep quality and health-related quality of life in patients with chronic fatigue syndrome/myalgic encephalomyelitis", J Sleep Res: e12703, doi:10.1111/jsr.12703, PMID 29770505
  16. ↑ Castro-Marrero, Jesús; Serrano-Pertierra, Esther; Oliveira-Rodríguez, Myriam; Zaragozá, Maria Cleofé; Martínez-Martínez, Alba; Blanco-López, María del Carmen; Alegre, José (2018), "Circulating extracellular vesicles as potential biomarkers in chronic fatigue syndrome/myalgic encephalomyelitis: an exploratory pilot study", Journal of Extracellular Vesicles, 7 (1), doi:10.1080/20013078.2018.1453730
  17. ↑ Calvo, Natalia; Pueyo, Natalia; Gutiérrez, Fernando; Ferrer, Marc; Castro-Marrero, Jesús; Alegre, José; Casas, Miquel; Ramos Quiroga, Josep-Antoni; Sáez-Francàs, Naia (July 2018). "Dimensional Personality Assessment among a Chronic Fatigue Syndrome (CFS) sample with Personality Inventory for DSM-5 (PID-5)". Actas Espanolas De Psiquiatria. 46 (4): 125–132. ISSN 1578-2735. PMID 30079926.
  18. ↑ Estévez-López, Fernando; Castro-Marrero, Jesus; Wang, Xia; Bakken, Inger Johanne; Ivanovs, Andrejs; Nacul, Luis; Sepúlveda, Nuno; Strand, Elin B.; Pheby, Derek; Alegre, José; Scheibenbogen, Carmen; Shikova, Evelina; Lorusso, Lorenzo; Capelli, Enrica; Sekulic, Slobodan; Lacerda, Eliana; Murovska, Modra (September 1, 2018). "Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review". BMJ Open. 8 (9): e020817. doi:10.1136/bmjopen-2017-020817. ISSN 2044-6055. PMID 30181183.
  19. ↑ Castro-Marrero, Jesús; Zaragozá, Maria Cleofé; Domingo, Joan Carles; Martinez-Martinez, Alba; Alegre, José; von Schacky, Clemens (December 2018). "Low omega-3 index and polyunsaturated fatty acid status in patients with chronic fatigue syndrome/myalgic encephalomyelitis". Prostaglandins, Leukotrienes and Essential Fatty Acids. 139: 20–24. doi:10.1016/j.plefa.2018.11.006. ISSN 0952-3278.
  20. ↑ Castro-Marrero, Jesús; Faro, Mónica; Zaragozá, María Cleofé; Aliste, Luisa; de Sevilla, Tomás Fernández; Alegre, José (December 2019). "Unemployment and work disability in individuals with chronic fatigue syndrome/myalgic encephalomyelitis: a community-based cross-sectional study from Spain". BMC Public Health. 19 (1). doi:10.1186/s12889-019-7225-z. ISSN 1471-2458. PMC 6599355. PMID 31253111.
  21. ↑ Escorihuela, Rosa María; Capdevila, Lluís; Castro, Juan Ramos; Zaragozà, María Cleofé; Maurel, Sara; Alegre, José; Castro-Marrero, Jesús (December 2020). "Reduced heart rate variability predicts fatigue severity in individuals with chronic fatigue syndrome/myalgic encephalomyelitis". Journal of Translational Medicine. 18 (1): 4. doi:10.1186/s12967-019-02184-z. ISSN 1479-5876. PMC 6943898. PMID 31906988.
  22. ↑ Cheema, Amanpreet K.; Sarria, Leonor; Bekheit, Mina; Collado, Fanny; Almenar‐Pérez, Eloy; Martín‐Martínez, Eva; Alegre, Jose; Castro‐Marrero, Jesus; Fletcher, Mary A.; Klimas, Nancy; Oltra, Elisa; Nathanson, Lubov (April 14, 2020). "Unravelling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Gender-specific changes in the microRNA expression profiling in ME/CFS". Journal of Cellular and Molecular Medicine. 00: 1–13. doi:10.1111/jcmm.15260. ISSN 1582-4934. PMID 32291908.
  23. ↑ Estévez-López, Fernando; Mudie, Kathleen; Wang-Steverding, Xia; Bakken, Inger Johanne; Ivanovs, Andrejs; Castro-Marrero, Jesús; Nacul, Luis; Alegre, Jose; Zalewski, Paweł; Słomko, Joanna; Bolle Strand, Elin; Pheby, Derek; Shikova, Evelina; Lorusso, Lorenzo; Capelli, Enrica; Sekulic, Slobodan; Scheibenbogen, Carmen; Sepúlveda, Nuno; Murovska, Modra; Lacerda, Eliana (May 2020). "Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology". Journal of Clinical Medicine. 9 (5): 1557. doi:10.3390/jcm9051557.

A chemical compound produced by, or involved in, metabolism. The term is often used to refer to the degradation products of drugs in the body.

metabolite A chemical compound produced by, or involved in, metabolism. The term is often used to refer to the degradation products of drugs in the body.

circadian rhythm Physical, mental, and behavioral changes that follow a 24-hour cycle, responding mostly to light and dark. Controlled the brain's hypothalamus. (Learn more: www.nigms.nih.gov)

See Diagnostic and Statistical Manual of Mental Disorders.

Diagnostic and Statistical Manual of Mental Disorders (DSM) - A psychiatric reference book published by the American Psychiatric Association, often referred to as "the psychiatrist's Bible". Although the most recent version (DSM-5) purports to be the authoritative guide to the diagnosis of mental disorders, the editors of both previous versions of the manual have heavily criticized the current version due to the climate of secrecy that shrouded the development of the latest version. 69% of the people who worked on DSM-5 reported having ties to the pharmaceutical industry. Dr. Allen Frances, who headed the development of the previous version, warned of dangerous unintended consequences such as new false 'epidemics'. The British Psychological Society criticized DSM-5 diagnoses as "clearly based largely on social norms, with 'symptoms' that all rely on subjective judgements" and expressed a major concern that "clients and the general public are negatively affected by the continued and continuous medicalisation of their natural and normal responses to their experiences". A petition signed by over 13,000 mental health professionals stated that the lowered diagnostic thresholds in DSM-5, combined with entirely subjective criteria based on western social norms, would "lead to inappropriate medical treatment of vulnerable populations". The director of the US National Institute of Mental Health, Dr. Thomas R. Insel, pointed out that the diagnoses in DSM-5 had no scientific validity whatsoever. (Learn more: www.scientificamerican.com)

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

(HR) - the number of times the heart beats within a certain time period, usually a minute[1]

heart rate (HR) - the number of times the heart beats within a certain time period, usually a minute

T cell A type of white blood cell which is mostly produced or matured in the thymus gland (hence T-cell) and is involved in the adaptive immune response on a cellular level. Also known as a T lymphocyte. (Learn more: www.youtube.com)

mitochondria Important parts of the biological cell, with each mitochondrion encased within a mitochondrial membrane. Mitochondria are best known for their role in energy production, earning them the nickname "the powerhouse of the cell". Mitochondria also participate in the detection of threats and the response to these threats. One of the responses to threats orchestrated by mitochondria is apoptosis, a cell suicide program used by cells when the threat can not be eliminated.

coenzyme Q10 (CoQ10) - Coenzyme Q10 (also known as ubiquinone) is found in the mitochondria and, as a component of the electron transport chain, plays an important role in aerobic respiration. The chemically-reduced form of CoQ10 is called ubiquinol.

extracellular vesicle An extracellular vesicle (sometimes abbreviated EV) is a piece of a cell that has broken off and formed a separate membrane-bound vesicle. A membrane-bound vesicle is like a bubble, or like a mini-cell, in that it has a membrane surrounding some liquid. An extracellular vesicle may also contain some parts of the cell from which the extracellular vesicle arose. There are currently two types of extracellular vesicles: "exosomes" and "microvesicles". An "exosome" is an extracellular vesicle that began inside the cell as an intracellular vesicle known as an "endosome". A "microvesicle" is an extracellular vesicle that begins at the cell surface, and pinches off the cell's own membrane to form a separate vesicle. (Learn more: journals.physiology.org)

extracellular vesicle An extracellular vesicle (sometimes abbreviated EV) is a piece of a cell that has broken off and formed a separate membrane-bound vesicle. A membrane-bound vesicle is like a bubble, or like a mini-cell, in that it has a membrane surrounding some liquid. An extracellular vesicle may also contain some parts of the cell from which the extracellular vesicle arose. There are currently two types of extracellular vesicles: "exosomes" and "microvesicles". An "exosome" is an extracellular vesicle that began inside the cell as an intracellular vesicle known as an "endosome". A "microvesicle" is an extracellular vesicle that begins at the cell surface, and pinches off the cell's own membrane to form a separate vesicle. (Learn more: journals.physiology.org)

The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

BMJ The BMJ (previously the British Medical Journal) is a weekly peer-reviewed medical journal.

Retrieved from "https://me-pedia.org/w/index.php?title=José_Alegre&oldid=241293"